Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma

Journal of the American Academy of Dermatology

Volumn 42, Issue 1 I, 2000, Pages 64-69

  Yamane, Kenichi ^a   Ihn, Hironobu ^a   Kubo, Masahide ^a   Yazawa, Norihito ^a   Kikuchi, Kanako ^a   Soma, Yoshinao ^a   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD LEVEL; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC SCLEROSIS;

EID: 0033939885     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(00)90010-0     Document Type: Article

References (33)

1. Rodnan GP. When is scleroderma not scleroderma? Bull Rheum Dis 1981;31:7-10.
2. Scarola JA, Shulman LE. Serologic abnormalities and their significance in localized scleroderma [abstract]. Arthritis Rheum 1975;18:526.
3. Rodnan GP, Rabin BS, Reichlin M. Eosinophilia and serological abnormalities in linear localized scleroderma [abstract]. Arthritis Rheum 1977;20:133.
4. Takehara K, Moroi Y, Nakabayashi Y, Ishibashi Y. Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983;26: 612-6.
5. Woo TY, Rasmussen JE. Juvenile linear scleroderma associated with serological abnormalities. Arch Dermatol 1985;121:1403-5.
6. Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP. Linear scleroderma: clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986;104:849-57.
7. Takehara K, Kikuchi K, Soma Y, Igarashi A, Ishibashi Y. Anti-single-strand DNA antibody and muscle involvement in localized scleroderma. Arch Dermatol 1990;126:1368-9.
8. Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K et al. Antihistone antibodies in localized scleroderma. Arthritis Rheum 1993;36:1137-41.
9. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995;287:193-7.
10. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. Br J Dermatol 1996;134: 843-7.
11. Ihn H, Fujimoto M, Sato S , Kikuchi K, Igarashi A, Soma Y, et al. Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma. J Am Acad Dermatol 1994;31:591-5.
12. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59:1203-11.
13. Rice GE, Munro JM, Corless C, Bevilacqua MP. Vascular and non-vascular expression of INCAM-110: a target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 1991;138:385-93.
14. Miyake K, Medina K, Ishihara K, Kimoto M, Auerbach R, Kincade PW. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J Cell Biol 1991;114:557-65.
15. Seron D, Cameron JS, Haskard DO. Expression of VCAM-1 in the normal and diseased kidney. Nephrol Dial Transplant 1991;6:917-22.
16. Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. α4/β1 Integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol 1992;149:1424-31.
17. Elices MJ, Osborn L, Takada Y , Crouse C, Luhowskyj S, Hemler ME, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/ fibronectin binding site. Cell 1990;60:577-84.
18. Ruegg C, Postigo AA, Sikorski EE, Butcher EC, Pytela R, Erie DJ. Role of integrin α4β7/α4βP in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol 1992;117:179-89.
19. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci 1989;84:9238-42.
20. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor of neutrophils related to complement regulatory proteins and lectins. Science 1989;243:1160-5.
21. Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, Hakomori S, et al. ELAM-1 mediates cell adhesion by recognition of a carbonhydrate ligand, sialyl-Lex. Science 1990;250: 1130-2.
22. Berg EL, Robinson MK, Mansson O, Butcher EC, Magnani JL. A carbohydrate domain common to both sialyl-Lea and sialyl-Lex is recognized by the endothelial cell leucocyte adhesion molecule ELAM-1. J Biol Chem 1991;266:14869-72.
23. Newman W, Beall LD, Carson CW , Hunder GG, Graben N, Randhawa ZI, et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993;150:644-54.
24. Leca G, Mansur SE, Bensussan A. Expression of VCAM-1 (CD106) by a subset of TCRδ-bearing lymphocyte clones: involvement of a metalloprotease in the specific hydrolytic release of the soluble isoform. J Immunol 1995;154:1069-77.
25. Masson JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecules in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus: lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum 1993; 36:519-27.
26. Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W. Soluble E-selectin is increased in inflammatory synovial fluid. J Rheumatol 1994;21:605-11.
27. Gruschwitz MS, Hornstein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995;38:184-9.
28. Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993;20:809-14.
29. Hebbar M, Lassalle P, Jannin A, Vanhee D, Bisiau S, Hatron PY, et al. E-selectin expression in salivary endothelial cells and sera from patients with systemic sclerosis: role of resident mast cell-derived tumor necrosis factor. Arthritis Rheum 1995;38:406-12.
30. Ihn H,Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998;37:1188-92.
31. Subcommittee for Scleroderma Criteria of the ARA Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-9.
32. Thornhill MH, Haskard DO. IL-4 regulates endothelial cell activation by IL-1, tumor necrosis factor, or IFN-γ. J Immunol 1990; 145:865-72.
33. Wellicome SM, Thornhill MH, Pitzalis C, Thomas DS, Lanchbury JS, Panayi GS, et al. A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor,IL-1, or lipopolysaccharide. J Immunol 1990;144:2558-65.